Neisseria meningitidis Native Outer Membrane Vesicles Containing Different Lipopolysaccharide Glycoforms as Adjuvants for Meningococcal and Nonmeningococcal Antigens

Bacterial Lipopolysaccharide

“…It is important to point out that the use of these LPS variants in vaccines also stimulated the generation of protective anti-LPS antibodies, providing added value to the use of nOMVs extracted from low-toxicity LPS versus standard procedures. Moreover, their use allows alterations in core regions of LPS with potential beneficial immunostimulatory activities (Nagaputra et al 2014). However, the three LPS species differ in their biological activities in humans and experimental animals, varying therefore in their use in nOMV vaccines.…”

Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: Lessons of the Normandy campaign

“…These data imply that a tailor-made OMV vaccine might be requested in the future to control an outbreak due to an uncovered strain. Moreover, OMV have adjuvant properties [6]. They have therefore been included in 4CMenB/Bexsero® (using the preparation developed for MenZB, the OMV vaccine used in New Zealand) to increase both the immunogenicity and persistence of the immune response against the other vaccine components.…”

Adjuvant Effects Elicited by Novel Oligosaccharide Variants of Detoxified Meningococcal Lipopolysaccharides on Neisseria meningitidis Recombinant PorA Protein: A Comparison in Mice

“…Lipid A is synthesized through a series of acylation steps concluding with the addition of a sixth 12-carbon acyl chain by the enzyme LpxL1 [9] . Altered forms of LPS have been proposed as potential vaccine adjuvants [10] , [11] , [12] , [13] , [14] . Detoxifying LPS by disruption of lpxL1 (LpxL1 LPS) results in expression of penta-acylated lipid A, which has significantly lower toxicity than the usual hexa-acylated form, but retains the adjuvant properties [9] .…”

“…LPS glycoforms with varied oligosaccharide lengths can modulate DC activation and down-stream signalling, thus altering T-cell behaviour [15] , [16] . The adjuvant effect of a modified glycoform of lipopolysaccharide (LPS) (LgtB-LpxL1) on immune responses of mice to vaccination with meningococcal protein, tetanus toxoid, or meningococcal serogroup C capsular polysaccharide was recently demonstrated and compared to the responses induced by the non-modified glycoform Lpxl1 [14] .…”